Enhancing the Clinical Effectiveness of Depression Screening Using Patient-targeted Feedback in General Practices: The GET.FEEDBACK.GP Multicentre Randomized Controlled Trial
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,030
- 试验地点
- 10
- 主要终点
- Depression severity (Questionnaire: Patient Health Questionnaire-9)
研究概览
简要总结
The multi-center GET.FEEDBACK.GP randomized controlled trial is designed based on patients' needs and preferences. In order to evaluate the effect of feedback in the broader setting of primary care, a total of 1076 primary care patients with elevated levels of depression (PHQ-9 score ≥ 10) will be randomized into three groups who either receive a) patient-targeted and physician-targeted feedback of depression screening results, b) a physician-targeted feedback of depression screening results only, or c) no feedback of screening results. The primary study outcome is depression severity after 6 months, secondary outcomes include the patients' behavior and cognitions after the screening, depression care according to German guideline recommendations and the health economic evaluation.
详细描述
Major depression is one of the most significant clinical disorders. In primary care, every sixth patient suffers from increased depression level, which is associated with higher risk of suicide, increased risk of onset and progression of chronic physical conditions. Still, depression is under recognized and undertreated in primary care. Moreover, evidence regarding the efficacy of depression screening in primary care is insufficient to draw clear conclusions. Our previous mono-center depression screening trial in cardiac patients, provides first evidence that written patient-targeted feedback improves depression severity, encourages greater patient participation and engagement in mental health. To amplify these effects, the multi-center GET.FEEDBACK.GP randomized controlled trial is now designed based on patients' needs and preferences. In order to evaluate the effect of feedback in the broader setting of primary care, a total of 1076 primary care patients with elevated levels of depression (PHQ-9 score ≥ 10) will be randomized into three groups who either receive a) patient-targeted and physician-targeted feedback of depression screening results, b) a physician-targeted feedback of depression screening results only, or c) no feedback of screening results. The primary study outcome is depression severity after 6 months, secondary outcomes include the patients' behavior and cognitions after the screening, depression care according to German guideline recommendations and the health economic evaluation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Screening
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Gender: male, female, diverse
- •Maximum Age: no maximum age
- •Attendance in primary care with medical consultation
- •Age ≥ 18 years;
- •Sufficient language skills;
- •Informed consent
- •Patient Health Questionnaire-9 > 9 points
排除标准
- •Life threatening health status;
- •Severe somatic or/and psychological disorder that needs urgent treatment;
- •Known diagnosis of a depressive disorder
- •Current depression treatment
- •Acute suicidal tendency;
- •Severe cognitive or/and visual difficulties;
- •Not being able to fill out questionnaires
- •No contact details
结局指标
主要结局
Depression severity (Questionnaire: Patient Health Questionnaire-9)
时间窗: Six months after screening
Level of depression severity six months after screening (Patient Health Questionnaire-9)
次要结局
- Depression severity (Questionnaire: Patient Health Questionnaire-9)(One and twelve months after screening)
- Anxiety (Questionnaire: Generalized Anxiety Disorder-7)(One, six and twelve months after screening)
- Health economic Evaluation (Questionnaire: Client Sociodemographic and Service Receipt Inventory)(Six and twelve months after screening)
- Somatic symptom severity (Questionnaire: Somatic Symptom Scale-8)(One, six and twelve months after screening)
- Depression treatment(Six and twelve months after screening)
- Quality-adjusted life years (Questionnaire: EuroQol-5D)(Six and twelve months after screening)
